Oral inhalation results in pulmonary drug targeting and thereby reduces systemic side
effects, making it the preferred means of drug delivery for the treatment of respiratory …

Chemotherapy is one of the important methods to treat cancer, and the emergence of
multidrug resistance (MDR) is one major cause for the failure of cancer chemotherapy …

Several drugs approved for inhalation for the treatment of pulmonary diseases are
substrates of the adenosine triphosphate-binding cassette (ABC) transporter P-glycoprotein …

Abstract P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are two efflux
transporters which are expressed in the apical (ie airway lumen-facing) membranes of lung …

Introduction Drugs for the treatment of respiratory diseases are commonly administered by
oral inhalation. Yet surprisingly little is known about the pulmonary pharmacokinetics of …

Small cell lung cancer (SCLC), one of the most aggressive cancers, has a high mortality rate
and poor prognosis, and the clinical therapeutic outcomes of multidrug resistant SCLC are …

Multidrug resistance-associated protein 1 (MRP1/ABCC1) is an efflux transporter
responsible for the extrusion of endogenous substances as well as xenobiotics and their …

Multidrug resistance-associated protein-1 (MRP1/ABCC1) is highly expressed in human
lung tissues. Recent studies suggest that it significantly affects the pulmonary disposition of …

Malignant tumors contribute significantly to human mortality. Chemotherapy is a commonly
used treatment for tumors. However, due to the low selectivity of chemotherapeutic drugs …

In the lungs, the membrane transporter P-glycoprotein (P-gp) is expressed in the apical (ie
lumen-facing) membrane of airway epithelial cells and in the luminal (blood-facing) …